BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chang JY, Shim KN, Tae CH, Lee KE, Lee J, Lee KH, Moon CM, Kim SE, Jung HK, Jung SA. Triple therapy versus sequential therapy for the first-line Helicobacter pylori eradication. BMC Gastroenterol 2017;17:16. [PMID: 28109257 DOI: 10.1186/s12876-017-0579-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Long X, Chen Q, Yu L, Liang X, Liu W, Lu H. Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance. Helicobacter 2018;23:e12485. [DOI: 10.1111/hel.12485] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
2 Talebi Bezmin Abadi A, Yamaoka Y. Helicobacter pylori therapy and clinical perspective. Journal of Global Antimicrobial Resistance 2018;14:111-7. [DOI: 10.1016/j.jgar.2018.03.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
3 Murad H, Rafeeq M, Mosli M, Gari M, Basheikh M. Effect of sequential eradication therapy on serum osteoprotegerin levels in patients with Helicobacter pylori infection and co-existing inflammatory bowel disease. J Int Med Res 2021;49:3000605211060648. [PMID: 34851775 DOI: 10.1177/03000605211060648] [Reference Citation Analysis]
4 Lee JW, Kim N, Nam RH, Lee SM, Kwon YH, Sohn SD, Kim JM, Lee DH, Jung HC. Favorable outcomes of culture-based Helicobacter pylori eradication therapy in a region with high antimicrobial resistance. Helicobacter. 2019;24:e12561. [PMID: 30632237 DOI: 10.1111/hel.12561] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 9.7] [Reference Citation Analysis]
5 Jaka H, Mueller A, Kasang C, Mshana SE. Predictors of triple therapy treatment failure among H. pylori infected patients attending at a tertiary hospital in Northwest Tanzania: a prospective study. BMC Infect Dis 2019;19:447. [PMID: 31113384 DOI: 10.1186/s12879-019-4085-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
6 Miftahussurur M, Pratama Putra B, Yamaoka Y. The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy. Pharmaceuticals (Basel) 2020;13:E276. [PMID: 32998241 DOI: 10.3390/ph13100276] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Zhuge L, Wang Y, Wu S, Zhao RL, Li Z, Xie Y. Furazolidone treatment for Helicobacter Pylori infection: A systematic review and meta-analysis. Helicobacter. 2018;23:e12468. [PMID: 29480532 DOI: 10.1111/hel.12468] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
8 Kim M, Park J, Kang M, Yang J, Park W. Gain and loss of antibiotic resistant genes in multidrug resistant bacteria: One Health perspective. J Microbiol 2021;59:535-45. [PMID: 33877574 DOI: 10.1007/s12275-021-1085-9] [Reference Citation Analysis]
9 O'Connor A, Lamarque D, Gisbert JP, O'Morain C. Treatment of Helicobacter pylori infection 2017. Helicobacter 2017;22 Suppl 1. [PMID: 28891137 DOI: 10.1111/hel.12410] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]